Search
Sparfloxacin
go.drugbank.com/drugs/DB01208ApprovedWithdrawnSparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase.
Sibutramine
go.drugbank.com/drugs/DB01105ApprovedIllicitWithdrawnIt is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. … In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeUrsodeoxycholic acid
go.drugbank.com/drugs/DB01586ApprovedInvestigational[A256272] Due to its hydrophilicity, UDCA is less toxic than [cholic acid] or [chenodeoxycholic acid]. … [A256272,A256277] UDCA has been used to treat liver disease for decades: its first use in traditional medicine dates back more than a hundred years.
Products: T-RUXICOGadoxetic acid
go.drugbank.com/drugs/DB08884ApprovedInvestigationalEthoxybenzyl diethylenetriaminepentaacetic acid is the moiety that chelates with a gadolinium ion and forms a stable complex with it to make up the drug. … A263156] Gadoxetate is a unique gadolinium-based contrasting agent (GBCA) with both dynamic phase and hepatobiliary phase and thus has different pharmacokinetic and pharmacodynamic properties compared to
Triprolidine
go.drugbank.com/drugs/DB00427ApprovedFirst generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness.
Mixtures: Pediatex TD, Stahist TpOxogluric acid
go.drugbank.com/drugs/DB08845InvestigationalNutraceuticalOxogluric acid is sold as a dietary supplement to athletes to improve their performance by helping to remove excess ammonia, but it is not officially approved for this indication and only experimental … Oxogluric acid (α-Ketoglutarate) is not approved for any indication in the world but is an investigational drug in the United States.
Carglumic acid
go.drugbank.com/drugs/DB06775ApprovedInvestigationalCarglumic acid was approved by the U.S. Food and Drug Administration (FDA) on 18 March 2010.
Peginterferon beta-1a
go.drugbank.com/drugs/DB09122ApprovedInvestigationalSymptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. … It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021.
Carfentanil
go.drugbank.com/drugs/DB01535IllicitInvestigationalVet approvedCarfentanil was first synthesized in 1974 by a team of chemists at Janssen Pharmaceutica which included Paul Janssen. … Currently sufentanil, approximately 10–20 times less potent (500 to 1000 times the efficacy of morphine per weight) than carfentanil, is the maximum strength fentanyl analog for use in humans.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeInfluenza A virus A/Washington/19/2020 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB16727ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.